๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

โœ Scribed by Yoshiya Tanaka; Kazuhiko Yamamoto; Tsutomu Takeuchi; Norihiro Nishimoto; Nobuyuki Miyasaka; Takayuki Sumida; Yoshihito Shima; Kazuki Takada; Isao Matsumoto; Kazuyoshi Saito; Takao Koike

Publisher
Springer
Year
2007
Tongue
English
Weight
482 KB
Volume
17
Category
Article
ISSN
1439-7595

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

B cell depletion as a novel treatment fo
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab
โœ R. John Looney; Jennifer H. Anolik; Debbie Campbell; Raymond E. Felgar; Faith Yo ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 199 KB

## Abstract ## Objective Safer and more effective therapies are needed for the treatment of systemic lupus erythematosus (SLE). B lymphocytes have been shown to play fundamental pathogenic roles in SLE, and therefore, elimination of B cells with the use of rituximab may represent a new therapy for

Efficacy and safety of rituximab in mode
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
โœ Joan T. Merrill; C. Michael Neuwelt; Daniel J. Wallace; Joseph C. Shanahan; Kevi ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 499 KB ๐Ÿ‘ 2 views

## Abstract ## Objective B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in p

A multicenter study of outcome in system
A multicenter study of outcome in systemic lupus erythematosus. ii.
โœ Steven Rosner; Dr. Ellen M. Ginzler; Herbert S. Diamond; Max Weiner; Michael Sch ๐Ÿ“‚ Article ๐Ÿ“… 1982 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 585 KB

Causes of death were examined for 1,103 systemic lupus erythematosus patients who were followed from 1965 to 1978 at 9 centers that participated in the Lupus Survival Study Group. A total of 222 patients (20%) died. Lupus-related organ system involvement (mainly active nephritis) and infection were